Drug Profile

Relutrigine - Praxis-Precision-Medicines

Alternative Names: PRAX-562

Latest Information Update: 22 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Praxis Precision Medicines
Class Analgesics; Antiepileptic drugs; Small molecules
Mechanism of Action Sodium channel antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Epilepsy
New Molecular Entity Yes

Highest Development Phases

Phase II Epilepsy
No development reported Headache

Most Recent Events

13 Jan 2025 Praxis Precision Medicines plans to submit NDA for Epilepsy in 2026
28 Dec 2024 No recent reports of development identified for phase-I development in Epilepsy(Combination therapy, In volunteers) in USA (PO, Capsule)
18 Dec 2024 US FDA grants Rare pediatric disease designation (RPDD) for Relutrigine in Dravet syndrome

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com